|
1
|
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
|
Blood
|
2006
|
8.33
|
|
2
|
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
|
Cancer Cell
|
2011
|
7.37
|
|
3
|
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
|
Blood
|
2009
|
5.72
|
|
4
|
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
4.06
|
|
5
|
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
|
Blood
|
2004
|
3.76
|
|
6
|
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
|
Blood
|
2005
|
3.24
|
|
7
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
Blood
|
2003
|
3.18
|
|
8
|
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
|
Blood
|
2002
|
3.03
|
|
9
|
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
|
Blood
|
2007
|
2.91
|
|
10
|
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
|
Cancer
|
2004
|
2.78
|
|
11
|
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
|
J Clin Oncol
|
2006
|
2.22
|
|
12
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
Blood
|
2004
|
2.03
|
|
13
|
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
|
Cancer
|
2004
|
1.75
|
|
14
|
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.
|
Cancer Cell
|
2007
|
1.74
|
|
15
|
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
|
Blood
|
2006
|
1.73
|
|
16
|
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
|
Clin Cancer Res
|
2005
|
1.61
|
|
17
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
Blood
|
2003
|
1.57
|
|
18
|
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
|
Blood
|
2004
|
1.49
|
|
19
|
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.
|
Leuk Lymphoma
|
2014
|
1.40
|
|
20
|
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
|
Cancer
|
2006
|
1.36
|
|
21
|
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
|
Blood
|
2003
|
1.35
|
|
22
|
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
|
Blood
|
2003
|
1.31
|
|
23
|
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
|
Blood
|
2005
|
1.23
|
|
24
|
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
|
Blood
|
2007
|
1.18
|
|
25
|
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
|
Cancer
|
2004
|
1.18
|
|
26
|
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
|
Leuk Res
|
2009
|
1.16
|
|
27
|
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
|
Cancer
|
2002
|
1.13
|
|
28
|
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
|
Cancer Res
|
2002
|
1.12
|
|
29
|
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
|
Hematol Oncol
|
2006
|
1.11
|
|
30
|
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
|
Blood
|
2005
|
1.10
|
|
31
|
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
|
Clin Cancer Res
|
2004
|
1.08
|
|
32
|
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
|
Blood
|
2002
|
1.08
|
|
33
|
Chronic myelomonocytic leukemia: myeloproliferative variant.
|
Curr Hematol Rep
|
2004
|
1.07
|
|
34
|
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
|
Blood
|
2005
|
1.06
|
|
35
|
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
|
Leuk Res
|
2005
|
1.00
|
|
36
|
RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
|
Clin Cancer Res
|
2010
|
1.00
|
|
37
|
Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
|
Haematologica
|
2006
|
0.98
|
|
38
|
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
|
Mol Cancer Ther
|
2008
|
0.97
|
|
39
|
Myelodysplastic syndrome is not merely "preleukemia".
|
Blood
|
2002
|
0.94
|
|
40
|
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
|
Haematologica
|
2003
|
0.94
|
|
41
|
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
|
Blood
|
2002
|
0.92
|
|
42
|
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
|
Cancer
|
2007
|
0.92
|
|
43
|
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
|
Cancer
|
2003
|
0.91
|
|
44
|
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
|
Cancer
|
2002
|
0.88
|
|
45
|
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
|
Cancer
|
2005
|
0.88
|
|
46
|
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
|
Clin Cancer Res
|
2008
|
0.87
|
|
47
|
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.
|
Front Oncol
|
2013
|
0.85
|
|
48
|
Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.
|
Cancer
|
2002
|
0.85
|
|
49
|
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
|
Leuk Res
|
2002
|
0.84
|
|
50
|
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
|
J Clin Oncol
|
2005
|
0.83
|
|
51
|
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
|
Br J Haematol
|
2002
|
0.82
|
|
52
|
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.
|
Blood
|
2005
|
0.81
|
|
53
|
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
|
Leuk Res
|
2004
|
0.80
|
|
54
|
The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Cancer
|
2003
|
0.79
|
|
55
|
Diagnosis and management of chronic myelomonocytic leukemia.
|
Curr Hematol Malig Rep
|
2008
|
0.77
|
|
56
|
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
|
Cancer Chemother Pharmacol
|
2002
|
0.77
|
|
57
|
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
|
Br J Haematol
|
2004
|
0.76
|
|
58
|
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
|
Exp Hematol
|
2002
|
0.75
|
|
59
|
Indolent neuroendocrine tumor involving the bone marrow. A case report with a 9-year follow-up.
|
Arch Pathol Lab Med
|
2003
|
0.75
|
|
60
|
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
|
Leuk Res
|
2003
|
0.75
|
|
61
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
|
Leuk Res
|
2003
|
0.75
|